Strategic focus Target high-need fibrotic and cancer indications such as liver fibrosis, MASH-related liver disease, colorectal cancer, and tumor vaccine enhancement, presenting multiple near-term collaboration and licensing opportunities with pharma partners seeking novel galectin-based therapies.

Clinical momentum Active progression toward late-stage studies for belapectin with FDA support and upcoming trials, providing a compelling entry point for CROs, contract manufacturers, and strategic investors looking to back near-term value creation.

Strategic partnerships Focus on seeking partnerships to fund and co-develop programs as resources expand, offering potential partners access to unique carbohydrate-based galectin inhibitors with clearly defined development pathways and potential for foreign commercialization in select regions.

Board and leadership Recent board enhancements with seasoned medical and clinical expertise signal a credible, scientifically driven collaboration environment, appealing to biotech investors and enterprise collaborators valuing strong governance and clear strategic milestones.

Market signaling Active investor engagement and conference appearances indicate readiness to engage potential buyers or partners; leverage these events to schedule targeted discussions with decision-makers at large pharma and specialty companies pursuing fibrosis and oncology assets.